FY2025 EPS Estimates for Q32 Bio Raised by Leerink Partnrs

Q32 Bio Inc. (NASDAQ:QTTB) – Analysts at Leerink Partnrs raised their FY2025 EPS estimates for Q32 Bio in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.38) per share for the year, up from their previous forecast of ($5.32). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.20) per share. Leerink Partnrs also issued estimates for Q32 Bio’s FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.62) EPS and FY2028 earnings at ($2.50) EPS.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer lowered their price target on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday. Wells Fargo & Company reissued an “equal weight” rating and issued a $16.00 target price (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday. Leerink Partners reaffirmed a “market perform” rating and set a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday. Piper Sandler lowered their price objective on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, BMO Capital Markets cut their target price on shares of Q32 Bio from $64.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.86.

Q32 Bio Price Performance

Q32 Bio stock opened at $3.70 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. Q32 Bio has a one year low of $3.67 and a one year high of $53.79. The company has a market cap of $45.07 million, a P/E ratio of -0.26 and a beta of -0.46. The business has a fifty day moving average of $36.81 and a two-hundred day moving average of $34.13.

Hedge Funds Weigh In On Q32 Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new position in shares of Q32 Bio during the third quarter worth $33,000. BNP Paribas Financial Markets grew its holdings in Q32 Bio by 199.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock valued at $58,000 after purchasing an additional 864 shares in the last quarter. Rhumbline Advisers increased its stake in Q32 Bio by 11,681.5% during the 2nd quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock worth $137,000 after buying an additional 7,593 shares during the period. MetLife Investment Management LLC acquired a new position in Q32 Bio in the 3rd quarter worth $159,000. Finally, Franklin Resources Inc. purchased a new position in Q32 Bio in the 3rd quarter valued at about $225,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.